Palomäki A, Palotie A, Koskela J, et al. - This study’s findings demonstrate the lifetime risk of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) based on MUC5B mutation carrier status, indicating the potential of genomics for risk stratification of RA-ILD.

• In this study, 1,965 (0.7%) developed ILD by age 80 out of 293,972 individuals

• MUC5B increased the risk of ILD with a HR of 2.44 (95% CI: 2.22 to 2.68) among all individuals in the dataset.

• It was shown that 247 (3.6%) developed ILD among 6,869 patients diagnosed with RA.

• MUC5B was a strong risk factor of ILD with an HR similar to the full dataset in patients with RA (HR: 2.27, 95% CI: 1.75 to 2.95).

• The results showed that 16.8% were the lifetime risks of ILD (95% CI: 13.1% to 20.2%) for MUC5B carriers and 6.1% (95% CI: 5.0% to 7.2%) for MUC5B non-carriers.

• As per the findings, the difference between risks started to emerge at age 65, with a higher risk among men.